Idenix Pharmaceuticals Stock Rating Upgraded by UBS AG (IDIX)
Idenix Pharmaceuticals (NASDAQ:IDIX) was upgraded by UBS AG from a “neutral” rating to a “buy” rating in a research note issued on Monday, TheFlyOnTheWall.com reports. The firm currently has a $11.00 target price on the stock, up from their previous target price of $4.00. UBS AG’s price objective indicates a potential upside of 73.78% from the company’s current price.
Separately, analysts at Credit Suisse upgraded shares of Idenix Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research note to investors on Wednesday, October 16th. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $4.92.
Shares of Idenix Pharmaceuticals (NASDAQ:IDIX) traded up 0.96% on Monday, hitting $6.33. 1,352,395 shares of the company’s stock traded hands. Idenix Pharmaceuticals has a 1-year low of $2.93 and a 1-year high of $7.45. The stock’s 50-day moving average is $5.28 and its 200-day moving average is $4.50. The company’s market cap is $848.2 million.
Idenix Pharmaceuticals (NASDAQ:IDIX) last issued its quarterly earnings data on Wednesday, October 30th. The company reported ($0.25) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.21) by $0.04. Analysts expect that Idenix Pharmaceuticals will post $-0.92 EPS for the current fiscal year.
Idenix Pharmaceuticals, Inc (NASDAQ:IDIX) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.